Quick Answer
ALNYLAM PHARMACEUTICALS, INC. reported Research And Development Expense of $1.32 billion for the year ending 2025.
- ALNYLAM PHARMACEUTICALS, INC. showed an increase of +17.2% in Research And Development Expense from 2024 to 2025.
- This data is from ALNYLAM PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on February 12, 2026.
- XBRL data for this metric is available from 2008 to 2025 (18 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2010: $24.70 million | Q2 2010: $28.14 million | Q3 2010: $27.47 million | Q1 2011: $26.35 million | Q2 2011: $25.30 million | Q3 2011: $24.27 million | Q1 2012: $21.07 million | Q2 2012: $21.72 million | Q3 2012: $22.09 million | Q1 2013: $22.18 million | Q2 2013: $24.22 million | Q3 2013: $34.46 million | Q1 2014: $43.76 million | Q2 2014: $44.67 million | Q3 2014: $46.27 million | Q1 2015: $58.04 million | Q2 2015: $67.01 million | Q3 2015: $68.62 million | Q1 2016: $96.27 million | Q2 2016: $83.17 million | Q3 2016: $97.94 million | Q1 2017: $86.98 million | Q2 2017: $90.63 million | Q3 2017: $95.25 million | Q1 2018: $96.86 million | Q2 2018: $137.58 million | Q3 2018: $139.95 million | Q1 2019: $129.13 million | Q2 2019: $163.89 million | Q3 2019: $160.80 million | Q1 2020: $169.57 million | Q2 2020: $155.00 million | Q3 2020: $161.78 million | Q1 2021: $185.90 million | Q2 2021: $182.64 million | Q3 2021: $194.57 million | Q1 2022: $169.89 million | Q2 2022: $205.71 million | Q3 2022: $245.37 million | Q1 2023: $230.57 million | Q2 2023: $248.53 million | Q3 2023: $253.18 million | Q1 2024: $261.00 million | Q2 2024: $294.14 million | Q3 2024: $270.93 million | Q1 2025: $265.12 million | Q2 2025: $323.62 million | Q3 2025: $358.81 million.
- Over the full 18 years of available data (2008 to 2025), ALNYLAM PHARMACEUTICALS, INC.'s Research And Development Expense has grown by 1,262.2%.
- Historical annual values: Fiscal year 2025: $1.32 billion | Fiscal year 2024: $1.13 billion | Fiscal year 2023: $1.00 billion | Fiscal year 2022: $883.02 million | Fiscal year 2021: $792.16 million | Fiscal year 2020: $654.82 million | Fiscal year 2019: $655.11 million | Fiscal year 2018: $505.42 million | Fiscal year 2017: $390.64 million | Fiscal year 2016: $382.39 million | Fiscal year 2015: $276.50 million | Fiscal year 2014: $190.25 million | Fiscal year 2013: $112.96 million | Fiscal year 2012: $86.57 million | Fiscal year 2011: $99.30 million | Fiscal year 2010: $106.38 million | Fiscal year 2009: $108.73 million | Fiscal year 2008: $96.88 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: